Expiration date: 06/2024

The composition and form of issue:

Capsules. 1 capsule contains:

glucosamine hydrochloride 500 mg

chondroitin sulfate sodium 400 mg

excipients: stearic acid, magnesium stearate, manganese sulfate 

composition capsules: gelatin 

in bottles HDPE at 30, 60, and 100 PCs in cartons 1 a bottle.

Description pharmaceutical form:

Transparent hard gelatin capsules .

The contents of capsules: white or white with a yellowish tinge and inclusions of crystalline powder and odourless or with low specific smell.



Absorption. The bioavailability of glucosamine after oral administration of 25% (effect of "first passage" through the liver).

Metabolism. After absorption, the oral dose of radioactively labeled glucosamine initially detected in the plasma and later penetrates the tissue. The highest concentration found in the liver, kidneys and articular cartilage. About 30% of the dose long persist in the tissues of bones and muscles.

Elimination. Write mainly kidneys in an unmodified form partially through the intestines. T1/2 of the drug is 68 hours

Chondroitin sulfate

Absorption. When taking chondroitin sulfate orally once at a dose of 0.8 g or 2 times per day 0.4 g concentration in plasma increases during 24 h. the Absolute bioavailability is 12%.

Metabolism. Metabolized by desulfuromonas.

Elimination. Excreted by the kidneys.

Description pharmacological action:

Stimulates the regeneration of cartilage tissue. Glucosamine and chondroitin sulfate sodium is involved in the synthesis of connective tissue, helping to prevent processes of destruction of cartilage and stimulate regeneration of tissue.

Introduction of exogenous glucosamine increases the production of cartilage matrix and provides nonspecific protection against damage to the cartilage. Another possible effect of glucosamine is to protect damaged cartilage from metabolic destruction caused by NSAIDs and corticosteroids, as well as own moderate anti-inflammatory effect.

Chondroitin sulfate serves as additional substratum for the formation of healthy cartilage matrix. Hyaluronan stimulates the synthesis of proteoglycans and type II collagen, and also protects gialuronon from enzymatic degradation (by inhibiting the activity of hyaluronidase) supports the viscosity of synovial fluid, stimulates cartilage repair mechanisms and inhibits the activity of those enzymes (elastase, hyaluronidase) that break down cartilage.

In the treatment of osteoarthritis relieves symptoms and reduces the need for NSAIDs.


Degenerative-dystrophic diseases of joints and spine:

  • osteoarthritis stage I–III
  • low back pain.


  • hypersensitivity
  • severe chronic renal failure
  • pregnancy
  • lactation
  • children up to age 15 years.

With caution:

  • diabetes
  • bleeding tendency
  • bronchial asthma.

Application of pregnancy and breast-feeding:

Clinical data on the efficacy and safety of the drug for the treatment of colds during pregnancy and lactation (breastfeeding) no.

Side effects:

Theraflex is well tolerated by patients. Possible dysfunction of the gastrointestinal (pain in epigastria, flatulence, diarrhea, constipation), dizziness, headache, leg pain and peripheral edema, drowsiness, insomnia, tachycardia, allergic reactions.

Drug interactions:

Improves absorption of tetracyclines reduces the effects of semisynthetic penicillins and chloramphenicol. The product is compatible with NSAIDs and corticosteroids.

Chondroitin sulfate can potentiate the effects of anticoagulants.

Method of application and dose:

Inside, regardless of meals, squeezed small amounts of water.

Adults and children over 15 years — in the first 3 weeks appoint 1 caps. 3 times per day on subsequent days — 1 caps. 2 times a day.

The recommended duration of treatment is 3 to 6 months. If necessary, possibly re courses of treatment, the duration of which is determined individually.


Symptoms: cases of overdose are not known. Overdose of chondroitin sulfate possible hemorrhagic rash, nausea, vomiting.

Treatment: gastric lavage, symptomatic therapy.

Special instructions:

With the appearance of adverse effects from the gastrointestinal tract, the dose should be reduced in 2 times, and if no improvement — stop the drug.